Fexlamose

Fexlamose is an investigational new drug that is being developed by Aer Therapeutics for the treatment of chronic obstructive pulmonary disease. It is mucolytic agent that contains a thiol linked to a saccharide that undergoes thiol–disulfide exchange with mucin disulfide bridges thereby breaking those bonds between mucin subunits and reducing the viscosity of mucin.
Wikipedia contributors, "Fexlamose", Wikipedia, revision 1385555952, retrieved 20 November 2026, source, CC BY-SA 4.0.